Recently, we found that galectin-3 (Gal-3) highly expressed on the cell membrane of drug-resistant colon cancer cells, and modified citrus pectin (MCP) could selectively bind with Gal-3 [15–17]. This evidence concerns the gene LGALS3 and malignant colon neoplasm.